PK Interaction of Ilaprazole and Aceclofenac in Healthy Adults

Phase 1, randomised, open-label trial of ilaprazole in Peptic ulcer disease (PUD) and gastroesophageal reflux disease (GERD) (6 arms), sponsored by Il-Yang Pharmaceutical. Primary endpoints: Maximum Plasma Concentration at Steady State at 12 hours and Area Under the Curve Over Dosing Interval at Steady State at 12 hours. Started Nov 2022; status: completed.